ALC
Alcon Inc.
Set alert
- YTD
- -9.34%
- 1 year
- -3.78%
- Open
- 72.34
- Prev close
- 71.13
- Mkt cap
- 34.54B
- Vol
- 1.61M
- Avg vol
- 1.69M
- EPS
- 1.32
- P/E
- 54.13
- Div yield
- 0.51%
More statistics
- Low
- 71.27
- High
- 72.67
- Forward P/E
- 18.08
- Beta
- 0.73
- Short ratio
- 10.62
- Inst. own
- 62.56%
- Dividend
- 0.36
- Ex-div date
- May 5, 2026
- Earnings
- Nov 10, 2026
- 50-d avg
- 67.67
- 200-d avg
- 71.99
- 1y target
- 81.98
Key statistics
- Market cap
- 34.55B
- Enterprise value
- 38.23B
- Trailing P/E
- 54.14
- Forward P/E
- 18.08
- PEG ratio
- 1.28
- Price / sales
- 3.18
- Price / book
- 1.60
- EPS (TTM)
- 1.32
- Beta
- 0.73
- Dividend yield
- 0.51%
- Payout ratio
- 26.56%
- Profit margin
- 5.92%
- Revenue (TTM)
- 10.86B
- Revenue growth
- 8.70%
- Free cash flow
- 1.27B
- Total cash
- 1.46B
- Total debt
- 5.30B
- Return on equity
- 2.94%
- Shares outstanding
- 483.40M
- Short % of float
- 0.00%
- 50-day average
- 67.67
- 200-day average
- 71.99
Analyst view
Consensus: buy
- Target (low)
- 62.00
- Target (mean)
- 81.98
- Target (high)
- 103.00
- Strong buy4
- Buy17
- Hold5
- Sell0
- Strong sell1
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate 0.89001.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | 0.89 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | 0.77 | 0.84 | +0.07 | +9.09% |
| May 5, 2026 | Mar 31, 2026 | 0.80 | 0.85 | +0.05 | +6.25% |
| Feb 24, 2026 | Dec 31, 2025 | 0.79 | 0.78 | -0.01 | -1.27% |
| Nov 11, 2025 | Sep 30, 2025 | 0.77 | 0.79 | +0.02 | +2.60% |
| Aug 19, 2025 | Jun 30, 2025 | 0.71 | 0.76 | +0.05 | +7.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Keybanc | main | Overweight | Overweight |
| Oct 21, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | BTIG | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Sep 22, 2026 | Jefferies | main | Buy | Buy |
| Sep 15, 2026 | Needham | reit | Buy | Buy |
About Alcon Inc.
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Switzerland
- Website
- alcon.com
News
- Keybanc Maintains Overweight on Alcon, Lowers Price Target to $84
- Alcon Acquires Neurotech Pharmaceuticals For $550M
- Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio.
- Barclays Initiates Coverage On Alcon with Equal-Weight Rating, Announces Price Target of $70
- Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
- Why Is Netflix Stock Falling on Monday?
- Bill Ackman’s New Stock Picks Are Here. These ETFs Could Be Worth Watching
- Bill Ackman Lost $400 Million on NFLX Stock in 2022 — Now He’s Back With a 3.15M-Share Bet, Saying Netflix Has ‘Won the Streaming Wars’ (UPDATED)
- JP Morgan Maintains Neutral on Alcon, Raises Price Target to $78.4
- Mizuho Maintains Outperform on Alcon, Raises Price Target to $85
Your note
Sign in to keep a note on ALC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 2.95% | 14,749,582 | 1.05B | Jun 29, 2026 |
| Bank Of New York Mellon Corporation | 2.61% | 13,057,962 | 933.25M | Jun 29, 2026 |
| NORGES BANK | 2.20% | 10,976,697 | 784.50M | Jun 29, 2026 |
| Invesco Ltd. | 2.08% | 10,380,332 | 741.88M | Jun 29, 2026 |
| Aristotle Capital Management, LLC | 2.00% | 9,979,069 | 713.20M | Jun 29, 2026 |
| AKO Capital LLP | 1.94% | 9,683,004 | 692.04M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund | 1.44% | 7,175,218 | 512.81M | Jul 30, 2026 |
| VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund | 0.95% | 4,758,876 | 340.12M | Jun 29, 2026 |
| iShares Trust-iShares Core MSCI EAFE ETF | 0.75% | 3,735,153 | 266.95M | Sep 29, 2026 |
| ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund | 0.66% | 3,283,650 | 234.68M | Aug 30, 2026 |
| VANGUARD WINDSOR FUNDS-Vanguard Windsor II Fund | 0.58% | 2,918,000 | 208.55M | Jul 30, 2026 |
| MFS SERIES TRUST X-MFS International Intrinsic Equity Fund | 0.48% | 2,417,516 | 172.78M | Aug 30, 2026 |